Google
SCYX — SCYNEXIS INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
SCYX FAQ
What is SCYX's P/E ratio?
SCYNEXIS INC (SCYX) currently trades at a P/E ratio of 3.76.
What is SCYX's ROE?
SCYNEXIS INC reports a Return on Equity (ROE) of -59.35%.
What is SCYX's dividend yield?
SCYNEXIS INC offers a dividend yield of 0.00%.
What is SCYX's Deepscope Quality Score?
Deepscope rates SCYX's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SCYX?
Deepscope's AI Timing Score for SCYX is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SCYX belong to?
SCYNEXIS INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 4.71
Price
-0.17
(-3.48%)
Day Change
|
|
|---|
SCYX, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 83 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.71 |
| PBV / Sector |
1.12 / 2.76
GREAT
|
| Earning Per Share | -2.50 |
| PE / Sector |
3.76 / 23.64
GREAT
|
| PEG or PE/Growth / Sector |
-0.03 / 0.13
|
| Average 1M Daily Value |
0.36 M
GREAT
|
| Average 1W Daily Value |
0.44 M
GREAT
|
| Timing Factors |
|
85% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:02 |
| Symbol | SCYX |
| Name | SCYNEXIS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 9.93 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 46.13 / 9,835.56 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548
Phone: 201 884 5485
Website: https://www.scynexis.com
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
